Can abiraterone acetate improve outcomes for metastatic prostate cancer? a large Real-World study investigates
NCT ID NCT07721532
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study observes how abiraterone acetate tablets work in real-world settings for Chinese men with metastatic prostate cancer. Researchers will track safety, side effects, and effectiveness, including PSA levels and survival. The goal is to understand how well the drug performs outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- abiraterone acetate tablets
- What this could lead to
- If successful, this study could provide real-world evidence on the safety and effectiveness of abiraterone acetate for metastatic prostate cancer, potentially guiding treatment decisions.
- What could go wrong
- As an observational study, it does not test a new treatment but collects data on existing use. Results may be influenced by patient selection and lack of a control group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
* Diagnosed with metastatic prostate cancer * Researchers assess eligibility to use abiraterone acetate tablets (II) for treatment, or previous use, or ongoing treatment with abiraterone acetate tablets (II)
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Queue One \& Queue Two: Age ≥ 18 years * Queue One \& Queue Two: Diagnosed with metastatic prostate cancer * Queue One: Researchers assess eligibility to use abiraterone acetate tablets (II) for treatment, or previous use, or ongoing treatment with abiraterone acetate tablets (II) * Queue One: Sign informed consent and voluntarily join this study * Queue 1: Male patients whose partners are women of childbearing potential should undergo surgical sterilization or agree to use effective contraception during the trial and for 3 weeks after the last administration of the study drug. * Queue Two: Previously used ordinary Abiraterone Acetate tablets continuously for more than 3 cycles * Queue 2: At least one efficacy assessment after medication Exclusion Criteria: * Queue One: Patients with severe liver dysfunction (Child-Pugh Class C) * Queue One: Currently participating in other clinical studies related to abiraterone acetate tablets (II) * Queue One \& Queue Two: Researchers determine other situations that are not suitable for inclusion in the study * Queue Two: Patients with severely missing medical record data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diagnosed with metastatic prostate cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower Hospital
Nanjing, China